Entity

Time filter

Source Type

Inashiki, Japan

Sato Y.,Eisai Co. | Bernier F.,Eisai Co. | Yamanaka Y.,EIDIA Co. | Aoshima K.,Eisai Co. | And 6 more authors.
Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring | Year: 2015

Background: We here examined whether plasma desmosterol-to-cholesterol ratio (DES/CHO) is decreased in patients with Alzheimer's disease (AD) and investigated the association between plasma DES/CHO and longitudinal cognitive decline. Methods: Plasma DES/CHO of AD patients and age-matched controls in a Japanese cross-sectional cohort was determined. Plasma DES/CHO at baseline and follow-up visits was assessed in relation to cognitive decline in Japanese and Swedish longitudinal cohorts. Results: Plasma DES/CHO was significantly reduced in Japanese AD patients and significantly correlated with Mini-Mental State Examination (MMSE) score. The longitudinal analysis revealed that plasma DES/CHO in AD patients shows a significant decrease at follow-up intervals. The decline in plasma DES/CHO is larger in the AD group with rapid progression than in that with slow progression. The changes in plasma DES/CHO significantly correlated with changes in the MMSE score. Conclusion: Plasma DES/CHO is decreased in AD patients and may serve as a longitudinal surrogate marker associated with cognitive decline. © 2015 The Alzheimer's Association. Source


Nagae A.,Biwako Gakuen Kusatsu Medical and Welfare Center for Children | Nagae A.,Shiga University of Medical Science | Kuwabara A.,Osaka Shoin Womens University | Tozawa K.,EIDIA Co. | And 3 more authors.
e-SPEN Journal | Year: 2013

Background & aims: We have investigated the possible risk factors for vitamin K deficiency in subjects with severe motor and intellectual disabilities (SMID). Methods: Eighty-two SMID patients were evaluated for their vitamin K intake, serum PIVKA (protein induced by vitamin K absence) -II and ucOC (undercarboxylated osteocalcin) levels; which are vitamin K-dependent hepatic and bone markers, respectively. Results: Thirty-six and 19 patients were receiving enteral nutrition (EN) and antibiotics, respectively. Although their serum levels were above the upper reference range in 52% of the subjects for PIVKA-II and 30% of those for ucOC, overt abnormalities in blood coagulation were not observed. Multivariate analyses revealed that EN and antibiotic treatment were significant predictors of the serum PIVKA-II and ucOC levels. Antibiotic treatment affected their serum levels differently in those with EN and those with oral intake (OI). In subjects without antibiotic treatment, vitamin K intake was significantly correlated with circulating levels of PIVKA-II and ucOC, and the breakpoints of vitamin K intake for PIVKA-II and ucOC were 2.5 μg/BW/day and 5.5 μg/BW/day, respectively. Conclusions: Vitamin K deficiency was highly prevalent in SMID patients, especially in those receiving both EN and antibiotics. Considering the facts that much more vitamin K is required in the bone than in the liver, and the SMID patients are at high risk of fracture, vitamin K supplementation would be of help in these subjects. © 2012 European Society for Clinical Nutrition and Metabolism. Source


Patent
Eidia Co and Sekisui Medical Co. | Date: 2010-06-30

The present invention aims to provide an assay reagent and an assay for accurately measuring KL-6, in particular, an assay reagent and an assay for accurately measuring KL-6 in samples containing a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor. KL-6 in samples that contain a rheumatoid factor and/or a nonspecific substance other than the rheumatoid factor can be accurately measured using an immunoassay reagent comprising a solution at a pH of 4.0 to 5.5 containing a rheumatoid factor interference inhibitor and a solution of an insoluble carrier on which anti-KL-6 antibodies are immobilized.


Patent
Eidia Co. and Sekisui Medical Co. | Date: 2012-05-23

A problem to be solved by the present invention is to inhibit a nonspecific agglutination reaction in an agglutination test using a monoclonal antibody having a property of specifically biding to PIVKA-II and a monoclonal antibody having a property of specifically biding to prothrombin as well as two types of carrier particles carrying these monoclonal antibodies. The nonspecific agglutination reaction can be inhibited by adding certain divalent metal ions to a reaction solution containing the monoclonal antibody having a property of specifically biding to PIVKA-II and the monoclonal antibody having a property of specifically biding to prothrombin as well as the two types of carrier particles carrying these monoclonal antibodies.


Usui M.,PALMA BeeZ Research Institute Co. | Usui M.,Nihon University | Usui M.,EIDIA Co. | Fujikawa T.,PALMA BeeZ Research Institute Co. | And 13 more authors.
Biochemical and Biophysical Research Communications | Year: 2015

We describe a novel technology for detecting nucleic acids: Probe Alteration Link Self-Assembly Reactions (PALSAR). PALSAR comprises DNA self-assembly of pairs of short DNA probes formed by alternate hybridization of three complementary regions in a pair of honeycomb probes (HCPs). Self-assembly occurs at designated salt concentrations and reaction temperatures and requires no enzymes. We prepared pairs of HCPs to detect mRNAs encoded by the GAPDH gene β-actin (BA) gene, CD3D gene, CD4 gene, major vault protein (MV) gene and the signalling lymphocytic activation molecule-associated protein (SAP) gene, and succeeded in quantitatively detecting these mRNAs. PALSAR could detect mRNA directly without synthesizing cDNA. Moreover, multiple mRNAs could be detected simultaneously in a single reaction tube and there was a good correlation between the results obtained PALSAR and those by real-time PCR. © 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. Source

Discover hidden collaborations